Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Immunotherapy that can activate immunity or enhance the immunogenicity of tumors has
emerged as one of the most effective methods for cancer therapy. Nevertheless, single …

Immunotherapy is being increasingly recognized as a key therapeutic modality to treat
cancer and represents one of the most exciting treatments for the disease. Fighting cancer …

Neoadjuvant ipilimumab+ nivolumab has demonstrated high pathologic response rates in
stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less …

The impact of cancer immunotherapy on clinical cancer care is growing rapidly. However,
different immunotherapies remedy distinct problems in cancer–immune system interactions …

Background: Although clinical studies have shown promise for targeting PD1/PDL1
signaling in non–small cell lung cancer (NSCLC), the regulation of PDL1 expression is …

Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor in adults.
With a median patient survival of less than two years, GBM represents one of the biggest …

Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis
remains poor. Therefore, the development of novel therapeutic strategies is urgently …

Abstract The programmed death-1 (PD-1) receptor serves as an immunologic checkpoint,
limiting bystander tissue damage and preventing the development of autoimmunity during …

Abstract Checkpoint programmed death-1 (PD-1)/programmed cell death ligands (PD-Ls)
have been identified as negative immunoregulatory molecules that promote immune …